Nxstage Medical, Inc. (NXTM) Misses Q2 EPS by 1c; Boosts FY14 Revs Outlook

Nxstage Medical, Inc. (NASDAQ: NXTM) reported Q2 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $74.1 million versus the consensus estimate of $70.52 million.

Nxstage Medical sees FY2014 revenue of $290 - $293 million, versus the consensus of $288.08 million.

For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• LTC Properties (LTC) PT Raised to $52 at RBC Capital
• Rivian reports Q3 2026 production of 19,751 vehicles